Free Trial

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Syndax Pharmaceuticals logo
$20.55 -0.34 (-1.63%)
As of 05/14/2026 04:00 PM Eastern

Syndax Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
0
Buy
12

Based on 13 Wall Street analysts who have issued ratings for Syndax Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 11 have given a buy rating, and 1 has given a strong buy rating for SNDX.

Consensus Price Target

$42.55
107.03% Upside
According to the 13 analysts' twelve-month price targets for Syndax Pharmaceuticals, the average price target is $42.55. The highest price target for SNDX is $57.00, while the lowest price target for SNDX is $34.00. The average price target represents a forecasted upside of 107.03% from the current price of $20.55.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for SNDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Syndax Pharmaceuticals and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNDX Analyst Ratings Over Time

TypeCurrent Forecast
5/15/25 to 5/15/26
1 Month Ago
4/15/25 to 4/15/26
3 Months Ago
2/14/25 to 2/14/26
1 Year Ago
5/15/24 to 5/15/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.55$40.33$37.20$35.91
Forecasted Upside107.03% Upside65.78% Upside81.64% Upside301.22% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

SNDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SNDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Syndax Pharmaceuticals Stock vs. The Competition

TypeSyndax PharmaceuticalsMedical CompaniesBroader Market
Consensus Rating Score
2.92
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside107.03% Upside1,808.04% Upside16.79% Upside
News Sentiment Rating
Neutral News

See Recent SNDX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/13/2026
UBS Group AG logo
UBS Group
4 of 5 stars
David Dai
David Dai
Not Rated
Lower TargetBuy$38.00 ➝ $37.00+83.90%
5/1/2026
Barclays PLC logo
Barclays
3 of 5 stars
Etzer Darout
Not Rated
Boost TargetOverweight$35.00 ➝ $37.00+86.30%
4/1/2026Boost TargetBuy$28.00 ➝ $34.00+46.05%
3/31/2026Lower TargetOutperform$45.00 ➝ $43.00+89.34%
3/30/2026Reiterated RatingBuy$48.00 ➝ $40.00+76.60%
3/27/2026 Reiterated RatingSell (D-)
3/9/2026Boost TargetOverweight$33.00 ➝ $45.00+81.89%
3/2/2026Boost TargetBuy$51.00 ➝ $57.00+159.07%
2/27/2026Set Target$45.00+107.28%
12/9/2025Reiterated RatingBuy$56.00+180.28%
10/27/2025Reiterated RatingBuy$40.00+195.64%
9/4/2025Initiated CoverageBuy$34.00+110.79%
8/6/2025 UpgradeStrong-Buy
5/6/2025Boost TargetSector Perform$16.00 ➝ $17.00+49.75%
8/15/2024 Boost TargetBuy$30.00 ➝ $31.00+53.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:00 AM ET.


SNDX Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Syndax Pharmaceuticals is $42.55, with a high forecast of $57.00 and a low forecast of $34.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There is currently 1 sell rating, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares.

According to analysts, Syndax Pharmaceuticals's stock has a predicted upside of 107.03% based on their 12-month stock forecasts.

Syndax Pharmaceuticals has been rated by research analysts at Barclays, Citigroup, Jefferies Financial Group, JPMorgan Chase & Co., Mizuho, Stifel Nicolaus, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Syndax Pharmaceuticals more than other "medical" companies. The consensus rating for Syndax Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how SNDX compares to other companies.


This page (NASDAQ:SNDX) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners